Optimizing HFrEF Patients Using BaroStim and CardioMems
Recruiting · NCT07399587 · Interventional (participants receive a specific treatment) · Lead sponsor: Northwell Health
View the official record on ClinicalTrials.gov →Interventions studied
BaroStim
What this trial is about
The goal of this study is to utilize CardioMems (measurement of pulmonary artery diastolic pressure) to assess BaroStim. At the time of CardioMems insertion, patients will be screened for candidacy to receive a BaroStim device. Patients will be followed for 3 months after the CardioMems insertion before undergoing insertion of a Barostim. Patients who have undergone a CardioMems, will be eligible for enrollment after 3 months of medication management and optimization. Patients will be followed for 1 year after insertion of Barostim.
Who can take part
Age range
18 Years to 80 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2, Phase 3
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Male or female, ages 18-80 years
- Diagnosed with NYHA Class III Heart Failure with LVEF\<35%
- Able to tolerate oral medications for guideline directed medical therapy titration period
- Have undergone insertion of CardioMems and BaroStim devices per standard of care.
- It is a standard of care to recommend that females of reproductive potential use highly effective contraception, because of the teratogenic potential of many medications used to treat HFrEF. In addition, withdrawal of GDMT during pregnancy may reverse the positive remodeling and lead to life threatening worsening of heart failure. Women of child-bearing age need to agree to use such a method during study participation and indefinitely after the end of the study.
Exclusion criteria
- Individuals ineligible for either CardioMems or BaroStim devices.
- NT-proBNP \>1600 mg/dL
- Indicated for CRT-D device (left bundle branch block)
- Initial 6-minute walk test distance less than 140 m
- Left ventricular assist device (LVAD)
- History of carotid vascular procedure (carotid endarterectomy)
- Pregnancy or lactation
- Known allergic reactions to components of the BaroStim or CardioMems insertion or guideline directed medical therapy for heart failure
- Febrile illness within 30 days of study enrollment
- Treatment with another investigational drug or other intervention within 1 year
- Current smoker or tobacco use within 1 year
- Enrolled in any other CVRx funded study, including investigator-initiated research, registries, or other pre- or post-market studies.
- Vulnerable individuals as outlined below
Where it is running
1 location listed across 1 US state.
- Peconic Bay Medical Center - Riverhead, New York, United States